### ðŸ«  Coronary Artery Disease: Pharmacoinvasive Management After Thrombolytic Therapy for STEMI

#### âœ… True Statements
1. For patients with **STâ€‘elevation myocardial infarction (STEMI)** who receive successful **thrombolytic therapy**, elective **invasive coronary angiography** is recommended **3 to 24 hours** after lysis as part of a **pharmacoinvasive strategy** to define coronary anatomy and enable complete revascularization.
2. **Thrombolytic therapy** is indicated for **STEMI** when symptom onset is **â‰¤12 hours** and **primary percutaneous coronary intervention (PCI)** cannot be performed within **120 minutes** of first medical contact.
3. Successful reperfusion after thrombolysis is demonstrated by **â‰¥50% resolution of maximal STâ€‘segment elevation** on followâ€‘up **electrocardiography (ECG)** performed **60â€“90 minutes** after lytic administration.
4. Routine **immediate (<3 hours) coronary angiography and PCI** after thrombolytic therapy are **not recommended** in patients with evidence of successful reperfusion because very early intervention increases bleeding and thrombotic complications without additional benefit.
5. **Coronary computed tomography angiography (CTA)** is **not recommended** for risk stratification in patients with **STEMI** treated with thrombolytics because invasive coronary angiography is already indicated before discharge.
6. **Noninvasive ischemia testing**, such as **exercise treadmill testing**, should **not** be performed prior to discharge when coronary angiography is planned after thrombolytic therapy for **STEMI**.

#### ðŸ’¬ Extra
1. Elective angiography improves outcomes by enabling complete revascularization of nonculprit lesions that contribute to future ischemic risk.
2. The mortality benefit of thrombolysis declines rapidly with treatment delay; primary PCI remains preferred when it can be performed within guideline time frames.
3. Failure to achieve the ECG reperfusion criterion signals failed lysis and mandates **rescue PCI**.
4. Very early routine PCI after lysis is reserved for patients without reperfusion or with clinical instability, where benefits outweigh bleeding risk.
5. CTA would neither change prognosis nor obviate the need for invasive angiography and thus adds cost and contrast exposure without benefit.
6. Stress testing offers no incremental information once all patients are destined for invasive evaluation.

#### ðŸ”· Tags
#Cardiology #EmergentCare #HospitalCare #PatientOver65 #STEMI #ThrombolyticTherapy #PharmacoinvasiveStrategy

#### ðŸ“™ Reference
Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. *JAMA*. 2022;327:662â€‘675. PMID: 35166796 doi:10.1001/jama.2022.0358

#### ðŸ†” Question ID
CVMCQ24002

#### ðŸ•’ Last Updated
February 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Coronary Artery Disease â€” Acute Coronary Syndromes â€” Treatment of STâ€‘Elevation Myocardial Infarction â€” Thrombolytic Therapy

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Thrombolytic therapy** may be considered for patients presenting **12â€“24 hours** after STEMI symptom onset when **hemodynamic instability** or extensive myocardium at risk exists and timely primary PCI is unavailable.
2. **Fibrinâ€‘specific thrombolytic agents** â€” **alteplase**, **reteplase**, and **tenecteplase** â€” achieve higher infarct artery patency and cause fewer allergic reactions than **streptokinase**.
3. **Intracerebral hemorrhage** occurs in approximately **1%** of patients receiving thrombolytics for **STEMI** and is often catastrophic.
4. All patients receiving thrombolysis should receive **aspirin 162â€“325â€¯mg** and **parenteral anticoagulation** with intravenous **unfractionated heparin**, **enoxaparin**, or **fondaparinux**, unless contraindicated.
5. A **300â€¯mg oral clopidogrel loading dose** administered with thrombolytic therapy increases infarct vessel patency and is recommended.
6. If the postâ€‘lytic **ECG** fails to show **â‰¥50% STâ€‘segment resolution** at **60â€“90 minutes**, **rescue PCI** should be performed promptly because it improves outcomes compared with conservative management.

#### ðŸ’¬ Extra
1. This 12â€“24â€‘hour window applies when transfer delays make primary PCI impossible and the patient remains at high ischemic risk.
2. Higher cost is the primary limitation to routine use of fibrinâ€‘specific agents despite their superior efficacy and safety profile.
3. Strict inclusion and exclusion criteria for thrombolysis aim to minimize catastrophic intracranial bleeding.
4. Dual antithrombotic therapy reduces reâ€‘occlusion and reinfarction after pharmacologic reperfusion.
5. Dual antiplatelet therapy with clopidogrel is continued until revascularization and subsequently per guideline recommendations.
6. The â‰¥50% STâ€‘segment resolution threshold is a validated surrogate marker for infarct artery patency and successful reperfusion.

#### ðŸ”· Tags
#ThrombolyticTherapy #FibrinSpecificAgents #BleedingRisk #AdjunctiveAntithromboticTherapy #RescuePCI #STEMI

### ðŸ“Š Supplemental Table

<!-- Contraindications and Cautions for Thrombolytic Therapy in STâ€‘Elevation Myocardial Infarction -->
<table border="1" cellpadding="6" cellspacing="0" style="border-collapse:collapse; width:100%; max-width:900px;">
  <caption style="font-weight:bold; text-align:left; padding-bottom:8px;">
    Contraindications and Cautions for Thrombolytic Therapy in STâ€‘Elevation Myocardial Infarction<sup>a</sup>
  </caption>

  <thead style="background-color:#e8e8e8;">
    <tr>
      <th style="text-align:left;">Absolute Contraindications</th>
    </tr>
  </thead>

  <tbody>
    <tr><td>Any previous intracranial hemorrhage</td></tr>
    <tr><td>Known structural cerebrovascular lesion (e.g., arteriovenous malformation)</td></tr>
    <tr><td>Known malignant intracranial neoplasm (primary or metastatic)</td></tr>
    <tr><td>Ischemic stroke within 3&nbsp;mo (except acute ischemic stroke within 4.5&nbsp;h)</td></tr>
    <tr><td>Suspected aortic dissection</td></tr>
    <tr><td>Active bleeding or bleeding diathesis (excluding menses)</td></tr>
    <tr><td>Significant closed head or facial trauma within 3&nbsp;mo</td></tr>
    <tr><td>Intracranial or intraspinal surgery within 2&nbsp;mo</td></tr>
    <tr><td>Severe uncontrolled hypertension (unresponsive to emergency therapy)</td></tr>
    <tr><td>For streptokinase: treatment within the previous 6&nbsp;mo</td></tr>

    <tr style="background-color:#e8e8e8;">
      <th style="text-align:left;">Relative Contraindications</th>
    </tr>

    <tr><td>History of chronic, severe, poorly controlled hypertension</td></tr>
    <tr><td>Severe uncontrolled hypertension on presentation (SBP &gt;180&nbsp;mm&nbsp;Hg or DBP &gt;110&nbsp;mm&nbsp;Hg)<sup>a</sup></td></tr>
    <tr><td>History of ischemic stroke (&gt;3&nbsp;mo previously)</td></tr>
    <tr><td>Dementia</td></tr>
    <tr><td>Known intracranial abnormality not covered in absolute contraindications</td></tr>
    <tr><td>Traumatic or prolonged (&gt;10&nbsp;min) CPR</td></tr>
    <tr><td>Major surgery within 3&nbsp;wk</td></tr>
    <tr><td>Recent (within 2â€‘4&nbsp;wk) internal bleeding</td></tr>
    <tr><td>Noncompressible vascular puncture site</td></tr>
    <tr><td>Pregnancy</td></tr>
    <tr><td>Active peptic ulcer disease</td></tr>
    <tr><td>Oral anticoagulant therapy</td></tr>
  </tbody>
</table>

<p style="font-size:smaller;"><em>CPR&nbsp;=&nbsp;cardiopulmonary resuscitation; DBP&nbsp;=&nbsp;diastolic blood pressure; SBP&nbsp;=&nbsp;systolic blood pressure.</em></p>
<p style="font-size:smaller;"><sup>a</sup>Viewed as advisory for clinical decision making and may not be allâ€‘inclusive or definitive.</p>
<p style="font-size:smaller;">Reprinted from O'Gara&nbsp;PT, Kushner&nbsp;FG, Ascheim&nbsp;DD, et&nbsp;al. 2013 ACCF/AHA guideline for the management of STâ€‘elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <em>J&nbsp;Am Coll Cardiol</em>. 2013;61:e78â€‘e140. PMID:&nbsp;23256914 doi:10.1016/j.jacc.2012.11.019. Â©2013, with permission from American College of Cardiology Foundation and the American Heart Association, Inc.</p>
